Topics

GSK partners with CEPI to develop vaccine for novel Coronavirus

03:03 EST 3 Feb 2020 | Pharmaceutical Business Review

Under the deal, GSK will provide its pandemic vaccine adjuvant technology to enhance the development of an effective vaccine against 2019-nCoV virus. Coronaviruses are a family of viruses

The post GSK partners with CEPI to develop vaccine for novel Coronavirus appeared first on Pharmaceutical Business review.

Original Article: GSK partners with CEPI to develop vaccine for novel Coronavirus

NEXT ARTICLE

More From BioPortfolio on "GSK partners with CEPI to develop vaccine for novel Coronavirus"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...